This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of meninges (meningeal cancer)Malignant Neoplasm of Meninges

Contents
A. Classification codes | B. Synonyms | C. Adult onset
1. History | 2. Causes | 3. Genetics | 4. General epidemiology | 5. Pathophysiology
6. Symptoms | 7. Signs | 8. Screening | 9. Diagnosis | 10. Treatment
11. Prognosis | 12. Prevention | 13. References
ItemDetails
A. Classification codesICD-10: C70 | Special Copayment Reduction: V193 | 5% copayment (for 5 years from the cancer patient registration date)
C70.0 cerebral meninges, C70.1 spinal meninges, C70.9 meninges, unspecified
B. SynonymsMalignant meningioma, anaplastic meningioma, meningeal sarcoma, WHO grade 3 meningioma, Malignant meningioma, Anaplastic meningioma, WHO grade 3 meningioma, Meningeal sarcoma
C. Adult onsetVery high — occurs mainly in adults in their 40s–70s, with female predominance; radiation-induced meningioma can appear in adulthood after childhood radiotherapy

1. History

The history of meningioma is closely linked to the development of neurosurgery in the 19th century. In 1614, Felix Platter first described a meningeal tumor, and in 1835 Bright systematically described its clinicopathologic features. Harvey Cushing, known as the father of neurosurgery, proposed the term 'meningioma' in 1922 and in 1938 published a monumental book analyzing more than 250 surgical cases, laying the cornerstone of meningioma research. Cushing established that meningiomas originate from meningothelial cells and are mostly benign tumors treatable by surgery.

The concept of malignant meningioma developed after the mid-20th century, when it was recognized that some meningiomas with poor prognosis have particular histologic features. The WHO first formalized the classification of brain tumors in 1979, and the meningioma grading system was subsequently refined through revisions in 2000 (3rd edition), 2007 (4th edition), 2016 (revised edition), and 2021 (5th edition). The 2021 WHO classification opened a new era of molecular marker-based grading by incorporating TERT promoter mutation and CDKN2A/B homozygous deletion as WHO grade 3 criteria. Radiation-induced meningioma (RIM) was recognized as an independent clinical entity when multiple, early-recurring, high-grade tumors were observed in cohorts of children who received cranial radiotherapy in the mid-20th century for leukemia or tinea capitis.

2. Causes

The strongest and best-established risk factor for malignant meningioma is exposure to ionizing radiation. The risk of meningioma increases markedly in patients who have received cranial radiotherapy (for childhood leukemia, tinea capitis, or after brain tumor treatment), and radiation-induced meningiomas tend to be more aggressive and higher grade than sporadic tumors. The radiation dose received and the latency period are known to be inversely related—a long latency (about 30–40 years) at low doses (<10Gy) and a short latency at high doses (>20Gy).

NF2 (neurofibromatosis type 2) gene variants are the most common genetic risk factor in sporadic and hereditary meningioma. Patients with NF2 who carry germline mutations in the NF2 gene (chromosome 22) develop multiple, early-onset meningiomas, and somatic NF2 variants are also observed in about 40–60% of sporadic meningiomas. Because the frequency is higher in women, it has been suggested that estrogen and progesterone receptor expression may be involved in the pathogenesis, but a direct causal relationship remains controversial. As for other risk factors, associations with past head trauma and mobile phone use have not been established to date.

3. Genetics

The molecular genetics of malignant meningioma (WHO grade 2/3) have advanced rapidly in recent years. In the 2021 WHO classification, TERT promoter mutation and CDKN2A/B homozygous deletion were included as molecular markers in the criteria for WHO grade 3 meningioma. TERT promoter mutations keep telomerase continuously active, allowing escape from cellular senescence, and are found in about 15% of WHO grade 3 meningiomas. Homozygous deletion of CDKN2A (encoding p16INK4a and p14ARF) removes cell-cycle arrest (G1/S checkpoint), allowing unlimited proliferation.

NF2 mutations are most common in meningothelial and fibrous meningiomas and are accompanied by monosomy 22. In meningiomas unrelated to NF2, TRAF7, KLF4, AKT1, SMO, and PIK3CA mutations are found, each associated with particular histologic types and locations (e.g., AKT1 E17K — meningothelial type, skull base). BAP1 mutation or deletion is found in clear cell and chordoid meningiomas and is associated with an aggressive clinical course. High-grade meningiomas additionally show CDKN2C deletion, TP53 variants, and 1p/10q/14q loss, suggesting a poor prognosis.

4. General epidemiology

Meningioma is the most common primary brain tumor, accounting for about 36% of all primary intracranial tumors, with an annual incidence of about 2.3 per 100,000 population. However, malignant (WHO grade 3) meningiomas account for only about 1.5–2% of all meningiomas. The distribution is WHO grade 1 80%, grade 2 18%, and grade 3 2%. The female-to-male ratio for all meningiomas is about 2:1, but the sex difference tends to narrow in high-grade meningiomas.

Incidence peaks in the 60s–70s and is rare in children and adolescents. Radiation-induced meningioma (RIM) arises in adulthood after a latency period following childhood radiotherapy, so it tends to be diagnosed at a relatively young age. In Korea, according to National Cancer Information Center statistics, brain and central nervous system cancers account for about 1–2% of all cancers, and meningioma is the most common after glioma and metastatic brain tumors. In Korea as well, incidental detection of asymptomatic meningiomas has increased since MRI became widespread.

5. Pathophysiology

Meningiomas originate from arachnoid cap cells within the arachnoid covering the brain and spinal cord. When a first genetic abnormality (NF2/other driver variant) occurs in a normal arachnoid cap cell, a benign tumor (WHO grade 1) forms. The accumulation of subsequent additional genetic abnormalities—CDKN2A/B deletion, TERT promoter mutation, TP53 variants, 1p/10q/14q loss, high-grade chromosomal instability—drives progression to higher grades. This is explained by the multistep carcinogenesis model.

Molecularly, the NF2 protein (merlin) is a tumor suppressor protein that inhibits cell growth via contact inhibition and the Hippo signaling pathway. Loss of merlin function → Hippo pathway inactivation → nuclear translocation of YAP/TAZ → activation of cell proliferation and survival genes is the key signaling pathway. In high-grade meningiomas, the PI3K-Akt-mTOR pathway and VEGF-mediated angiogenesis are additionally activated. Radiation-induced meningioma arises through a mechanism in which DNA double-strand breaks caused by ionizing radiation induce mutations of NF2 and other tumor suppressor genes.

6. Symptoms

The symptoms of malignant meningioma vary with tumor location, size, and growth rate. Most symptoms arise from increased intracranial pressure or compression of surrounding neural structures. Headache is the most common symptom, with a pattern of intracranial hypertension that is mainly worse in the morning and accompanied by nausea and vomiting. Seizures are common especially in meningiomas adjacent to the cerebral hemispheres and may be focal or generalized.

Focal neurologic deficits vary by tumor location. Meningiomas adjacent to the motor cortex cause unilateral motor paralysis or sensory abnormalities; posterior fossa tumors cause cerebellar ataxia, vertigo, and facial paralysis; tuberculum sellae tumors cause visual field defects and optic nerve compression; and cavernous sinus tumors cause ophthalmoplegia (diplopia) and facial pain. Cognitive decline and personality changes may appear with frontal lobe meningiomas. With spinal meninges involvement (C70.1), back pain, lower limb weakness, and bladder and bowel dysfunction are common. Malignant meningiomas are characterized by rapidly progressing symptoms.

7. Signs

On neurologic examination, papilledema is a direct sign of intracranial hypertension, confirmed on funduscopy by swelling and loss of margins of the optic nerve head. Focal neurologic deficit signs by location include unilateral pyramidal tract signs (positive Babinski, hyperactive deep tendon reflexes), hemiparesis, aphasia, visual field defects, cognitive impairment, and cranial nerve palsies. Spinal meningiomas may cause Brown-Séquard syndrome or bilateral pyramidal tract signs.

Signs of meningeal irritation (neck stiffness, Kernig's sign, Brudzinski's sign) may appear when there is leptomeningeal dissemination. High-grade meningiomas may be accompanied by malignant brain edema, causing altered consciousness, abnormal pupillary responses, and spinal herniation. On MRI, a uniformly and strongly enhancing thick dural tail (meningeal tail sign) is characteristic, but in malignant meningioma heterogeneous enhancement, brain invasion, and edema are prominent.

8. Screening

There is no general population screening program for malignant meningioma. However, regular MRI surveillance is recommended in high-risk groups. Patients with NF2 should be monitored for meningioma development and growth with annual or biennial brain and spinal MRI. Pediatric and adult patients with a history of radiotherapy should be aware of the risk of secondary meningioma and undergo MRI immediately if headache or neurologic symptoms develop.

For small asymptomatic meningiomas found incidentally (so-called meningioma incidentaloma), regular MRI follow-up (generally MRI within the first year, then at 3–5-year intervals) is recommended. Active treatment is considered if growth is rapid, edema is present, or symptoms appear. Currently, blood biomarker-based screening for early detection of malignant meningioma has not reached clinical application, but ctDNA (circulating tumor DNA) and circulating tumor cells are being studied. Molecular tests for WHO grade 3 determination (TERT promoter, CDKN2A deletion) are performed on postoperative tissue specimens.

9. Diagnosis

Diagnosis of malignant meningioma is made by integrating imaging with histopathologic and molecular genetic testing. Gadolinium-enhanced MRI is the gold standard for meningioma diagnosis, evaluating tumor morphology, location, brain invasion, edema, the meningeal tail sign, and invasion of adjacent structures. On MRI, malignant meningioma is characterized by heterogeneous enhancement, irregular margins, invasion of surrounding brain tissue, and extensive peritumoral edema. CT is used complementarily to evaluate calcification and bone invasion.

Histopathologic grading and molecular testing are performed on tissue specimens obtained by surgical biopsy and resection. The diagnostic criteria for WHO grade 3 are one or more of ① anaplastic cytomorphology (frankly malignant morphology), ② mitotic count >20/10 HPF, ③ TERT promoter mutation, and ④ CDKN2A/B homozygous deletion. In addition, immunohistochemistry (Ki-67 proliferation index, progesterone receptor, p16, SMARCE1) and FISH (1p/10q/14q loss) are used for prognostic stratification. Spinal MRI and cerebrospinal fluid cytology to evaluate leptomeningeal dissemination are also considered.

10. Treatment

The basic principle in treating malignant meningioma (WHO grade 2/3) is maximal safe resection. Complete resection (Simpson grade 1) by the Simpson grading classification is the goal, but preservation of functional neural structures takes priority. Because recurrence rates in high-grade meningiomas are high even after complete resection, postoperative radiotherapy is given as standard. Fractionated radiotherapy (54–60Gy/30 fractions) is the standard, and stereotactic radiosurgery (SRS, Gamma Knife/CyberKnife) is used for residual tumors or small recurrent tumors.

Chemotherapy is tried in repeatedly recurring or radioresistant malignant meningiomas, but its efficacy is generally limited. Hydroxyurea has been the most studied, but its clinical benefit is minimal. Bevacizumab (anti-VEGF) has been reported to have some stabilizing effect in recurrent meningioma. For somatostatin receptor inhibitors (octreotide, DOTATATE), because the receptors are highly expressed in meningiomas, their potential as targeted agents and in peptide receptor radionuclide therapy (PRRT) is being explored. In NF2-associated meningiomas, Hippo pathway (YAP/TAZ) and FAK inhibitors are under clinical investigation.

11. Prognosis

The prognosis of meningioma differs greatly by WHO grade. In WHO grade 1 (benign), the 5-year recurrence rate is 7–20% and the prognosis is very good. In WHO grade 2 (atypical), the 5-year recurrence rate is 29–52% and the 5-year mortality rate 20–30%. In WHO grade 3 (malignant/anaplastic), the 5-year recurrence rate reaches 50–78%, and 5-year survival is reported at about 20–60%, but below 50% in large datasets. Median overall survival is about 2–4 years.

Poor prognostic factors include high grade (WHO grade 3), incomplete resection, TERT promoter mutation, CDKN2A/B deletion, brain invasion, leptomeningeal dissemination, radiation-induced meningioma, and a high Ki-67 proliferation index. Radiation-induced meningiomas are more aggressive than sporadic tumors, with a high proportion of WHO grade 2 (43.6%) after initial resection and a recurrence rate reaching 41%. With repeated recurrence, the possibility of surgery decreases, and the prognosis worsens sharply when radioresistance develops.

12. Prevention

The key to preventing malignant meningioma is minimizing exposure to ionizing radiation. In medical radiotherapy, the minimum effective radiation dose should be used, and when cranial radiation is unavoidable, the patient should be fully informed of the risk of secondary tumors and a long-term surveillance plan established. In particular, cranial radiotherapy for noncancerous conditions in children (such as tinea) is no longer used.

Carriers of NF2 gene mutations should receive genetic counseling along with regular MRI monitoring. Genetic testing is recommended when there is a family history of multiple meningiomas, such as Beverly meningiomatosis. Because progesterone receptor expression is common in meningiomas, careful evaluation of hormone replacement therapy and exogenous hormone use is needed, but a direct causal relationship has not yet been established. When meningioma has already been diagnosed, regular MRI along with prompt neurologic and neurosurgical evaluation of symptom changes is important for early detection of recurrence.


13. References

  1. WHO Classification of Tumours, 5th Edition: Central Nervous System Tumours. IARC, 2021.
  2. Caccese M, et al. The role of radiation therapy and systemic treatments in meningioma. Cancer Med. 2023;12(9):10469847.
  3. Rogers L, et al. Malignant meningiomas: from diagnostics to treatment. PMC. 2025;PMC11898517.
  4. Krishnatry R, et al. Advances in molecular profiling of meningiomas. Front Oncol. 2026;PMC12333779.
  5. Wahab SH, et al. Molecular prognostication in grade 3 meningiomas and p16/MTAP IHC. Neuro-Oncol Adv. 2024;PMC10824160.
  6. Radiation-induced meningioma: growth rate and outcomes. PMC. 2021;PMC8211577.
  7. Cushing H, Eisenhardt L. Meningiomas: Their Classification, Regional Behaviour, Life History, and Surgical End Results. Springfield, IL; 1938.
  8. National Cancer Information Center. Brain and central nervous system cancer statistics. 2024.